Clinical trials in Montpellier – page 12

1 094 clinical trials in Montpellier, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Montpellier at a glance

1 094

clinical trials

Research sites4

Quick filters

1 094 trials in Montpellier

Open in trial search

Cutaneous lupus erythematosus

Recruiting

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Endometrial cancer+12

Recruiting

A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

InvestigationalNo placebo

A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Zanidatamab
Sponsor:Jazz Pharmaceuticals Ireland Limited

Contact Research Centre

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Facioscapulohumeral muscular dystrophy

Recruiting

A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy

Investigational

A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy

Investigational

France

Participants:18–64 years · 65+ years
Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dux4 Mrna Via A Non-Cleavable Linker
Sponsor:Avidity Biosciences Inc.

Contact Research Centre

Pleural mesothelioma

Recruiting

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Breast cancer+2

Recruiting

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Datopotamab Deruxtecan
Sponsor:AstraZeneca AB

Contact Research Centre

Asthma

Recruiting

Testing WIN378 Safety and Effects in Adults with Moderate or Severe Asthma

Investigational

Testing WIN378 Safety and Effects in Adults with Moderate or Severe Asthma

Investigational

France

Participants:18–64 years · 65+ years
Substances:HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST TSLP
Sponsor:Windward Bio AG

Contact Research Centre

Triple negative breast cancer

Recruiting

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sacituzumab Govitecan
Sponsor:Unicancer

Contact Research Centre

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Hereditary angioedema

Recruiting

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational

France

Participants:18–64 years · 65+ years
Substances:ADX-324
Sponsor:Adarx Pharmaceuticals Inc.

Contact Research Centre

Comparing Ursodeoxycholic Acid and Prednisone for Treating Liver Inflammation Caused by Cancer Immunotherapy in Adult Patients

Recruiting

Registered drugNo placebo

Comparing Ursodeoxycholic Acid and Prednisone for Treating Liver Inflammation Caused by Cancer Immunotherapy in Adult Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Centre Hospitalier Universitaire De Montpellier

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Montpellier

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, bladder cancer, and mantle cell lymphoma. Studies evaluate combination therapies and novel treatment approaches for improved patient outcomes.

Advanced HNSCC Treatment Combinations
Non-muscle Invasive Bladder Cancer Therapy
Gastric Cancer Targeted Treatments

Research includes evaluation of immunotherapy combinations and targeted molecular approaches.

02 Autoimmune Conditions

Studies examining innovative treatments for Crohn's disease, multiple sclerosis, and systemic sclerosis. Research focuses on novel therapeutic approaches and treatment optimization.

Fecal Microbiota Transplantation Studies
MS Treatment De-escalation Strategies
Advanced Autoimmune Therapies

Trials aim to improve disease management and patient quality of life.

03 Rare Diseases

Investigating treatments for achondroplasia, pyruvate dehydrogenase deficiency, and thyroid eye disease. Focus on developing targeted therapies for these uncommon conditions.

Growth Disorders in Children
Metabolic Disease Management
Innovative Therapeutic Approaches

Research aims to address unmet medical needs in rare disease populations.

04 Preventive Medicine

Clinical trials evaluating vaccines for cytomegalovirus, yellow fever, and HPV prevention. Studies focus on immunization effectiveness and safety profiles.

Vaccine Development Programs
Infection Prevention Strategies
Population Health Protection

Research emphasizes disease prevention and public health improvement.

Back to France All countries